Progyny Expands Maternal Health Support with Addition of Doula Services
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Progyny (Nasdaq: PGNY), a global leader in women's health and family building, is expanding its support throughout the maternal health journey with the addition of doula services. Currently pregnancy, childbirth, and perinatal conditions represent one of the largest shares of employer health spend in the U.S. The addition of in-person and virtual doula services to Progyny's comprehensive maternal offerings will further its ability to provide equitable, high-quality care that can improve outcomes across a diverse member population.
As the company formally rolls out its doula offering, Progyny is adding Pacify, a leading provider of maternity care solutions, to complement its team of specialty-trained, certified doulas and maternal health care providers. Individuals interested in doula services will be matched, creating trusted and personal connections with a doula who best fits their care needs and demographic preferences. Research suggests that doula support may help reduce C-section rates and NICU complications such as low birth weight babies. They also help reduce maternal health barriers, educating and empowering expectant mothers and helping to improve the overall birthing experience.
'Doulas are playing a powerful role in improving maternal health outcomes by serving as a resource for information, advocacy and support,' explained Janet Choi, MD, MSCP, Chief Medical Officer, Progyny. 'Our commitment to the health of our diverse member base means giving them access to the full spectrum of care, support, and resources from preconception to postpartum. This is how we continue to build their trust in Progyny to partner with them on their individual health journeys.'
'Both Pacify and Progyny share a commitment to offering families the comprehensive support they need throughout pregnancy, the birthing journey, and beyond. Doulas play a critical role providing evidence-based guidance and advocacy, and together with Progyny, we can provide high-quality care to more families during this transformative and often overwhelming stage of life,' said Jennifer Sargent, CEO of Pacify.
Progyny's Pregnancy and Postpartum program provides comprehensive maternity support to ensure members receive personalized, high-touch care throughout their journey, integrating proactive clinical coaching, education, and access to certified doulas and lactation specialists. Progyny's doula service is currently available as part of this offering. The service is available to support members across the pregnancy journey from prenatal care, virtual and physical support during labor, to emotional support, lactation and postpartum care, as well as miscarriage and loss support as needed. For more information, visit Progyny.com.
About Progyny:Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
About Pacify:Pacify is on a mission to build the most comprehensive, diverse, and culturally responsive doula care team across the country, connecting expectant and new parents to skilled and supportive professionals. With over a decade of experience, Pacify partners with public health agencies, health plans, and Medicaid MCOs to ensure every family has access to the personalized support they deserve. Through our innovative digital platform, families receive access to both virtual and in-person guidance from certified doulas and lactation consultants. Committed to improving healthcare equity, Pacify is breaking down barriers in maternal health, supporting parents, and transforming outcomes for future generations.
For Further Information, Please Contact:
ProgynyMedia:Alexis Fordmedia@progyny.com
Investors:James Hartinvestors@progyny.com
Pacify
Harlan SmithHarlan.Smith@Pacify.comSign in to access your portfolio

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum/PG would be discontinued due to futility. The recommendation came from the Independent Data Monitoring Committee/IDMC after an unblinded interim analysis of data from the first 30 enrolled patients. The IDMC noted no unexpected adverse events. Following the recommendation, InflaRx intends to halt further development of vilobelimab for the PG indication. The company will now re-prioritize its resources on INF904, which is an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. Topline Phase 2a data readouts for INF904 in chronic spontaneous urticaria/CSU and hidradenitis suppurativa/HS are anticipated in the summer of 2025. A technician carefully measuring the quality of a nutritional supplement. GOHIBIC (vilobelimab) remains available in the US under an Emergency Use Authorization/EUA granted by the FDA. The authorization is for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation/IMV or extracorporeal membrane oxygenation/ECMO. Vilobelimab is a first-in-class, intravenously delivered, anti-C5a monoclonal antibody that selectively blocks free C5a, which is a potent inflammatory mediator. InflaRx (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology in Germany and the US. While we acknowledge the potential of IFRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Tilray Medical Study Finds Oral THC:CBD Extract Offers Faster, Higher Bioavailability
Tilray Brands Inc. (NASDAQ:TLRY) is one of the best penny stocks under $1 to buy now. On June 26, Tilray Brands, through its medical division, Tilray Medical, published a new scientific study on the bioavailability of different cannabinoid formulations. This research, conducted on healthy volunteers, compared Tilray's oral THC:CBD extract with oromucosally administered nabiximols. A busy pharmaceutical lab with technicians developing hemp-derived CBD products. The findings show that Tilray's oral extract resulted in higher and faster concentrations of THC and CBD in the bloodstream. Tilray Brands Inc. (NASDAQ:TLRY) is a lifestyle consumer products company that researches, cultivates, processes, and distributes medical cannabis products in Canada, the US, Europe, Australia, New Zealand, Latin America, and internationally. While we acknowledge the potential of TLRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025
Mersana Therapeutics Inc. (NASDAQ:MRSN) is one of the best penny stocks under $1 to buy now. Earlier in June, Mersana Therapeutics presented additional positive interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting in Chicago, Illinois. Emi-Le is the company's B7-H4-directed Dolasynthen ADC. The presentation focused on data from Emi-Le's Phase 1 dose escalation and backfill cohorts, with a data cut-off of March 8, 2025. These cohorts included patients with triple-negative breast cancer/TNBC, hormone-receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma type 1 (ACC-1). A close-up of a hand holding a vial of biopharmaceutical drugs ready to be administered. The safety and tolerability profile of Emi-Le, as of March 8, data cut-off, was consistent with initial data reported in January this year, with no new safety signals observed. Mersana Therapeutics is focusing its initial expansion work on patients with TNBC who have been previously treated with a topoisomerase-1 inhibitor ADC, recognizing this as a population with high unmet need. Mersana Therapeutics Inc. (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates/ADC for cancer patients with unmet needs. While we acknowledge the potential of MRSN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data